Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Marco Del Chiaro

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7400-013X; OpenAlex author ID A5049269121. Sources: OpenAlex.

Their work

Papers
77 (first author 2, last author 27)
Trials
0
Grants
0
Labs led
1
Collaborators
318
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 3 papers · 2019: 8 papers · 2020: 8 papers · 2021: 12 papers · 2022: 4 papers · 2023: 7 papers · 2024: 10 papers · 2025: 8 papers · 2026: 10 papers

Papers 50 of 77

  1. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  2. Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis. Last author DOI 10.1016/j.hpb.2026.04.451↗
  3. Patterns of treatment and survival in borderline resectable and locally advanced pancreatic cancer. Last author DOI 10.1016/j.pan.2025.12.007↗
  4. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Last author DOI 10.1038/s41416-025-03294-w↗
  5. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  6. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  7. Portomesenteric Venous Thrombosis After Pancreatic Cancer Surgery With Venous Resection and Reconstruction: Timing, Incidence, and Risk Factors. Last author DOI 10.1097/sla.0000000000006605↗
  8. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Last author DOI 10.1097/sla.0000000000006638↗
  9. Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-025-18426-y↗
  10. ASO Visual Abstract: Neoadjuvant Therapy for Invasive Intraductal Papillary Mucinous Neoplasms: a Comparative Study with Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-025-18603-z↗
  11. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  12. Adjuvant therapy after resection of intraductal papillary mucinous neoplasm-derived pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ctrv.2025.102969↗
  13. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Co-author DOI 10.1038/s41416-025-03025-1↗
  14. Importance of increasing resection rates in pancreatic cancer treatment. Co-author DOI 10.1093/bjsopen/zraf029↗
  15. Oligometastatic pancreatic cancer: current state of management and emerging therapies. Co-author DOI 10.1093/oncolo/oyaf154↗
  16. Validation of the PANAMA Score for Survival and Benefit of Adjuvant Therapy in Patients With Resected Pancreatic Cancer after Neoadjuvant FOLFIRINOX. Co-author DOI 10.1097/sla.0000000000006650↗
  17. Surgery for Borderline Resectable and Locally Advanced Pancreatic Cancer with Arterial Encasement after Neoadjuvant Therapy: A Single-center Experience. Last author DOI 10.1097/sla.0000000000006690↗
  18. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  19. Pathological Complete Response in Patients With Resected Pancreatic Adenocarcinoma After Preoperative Chemotherapy. Last author DOI 10.1001/jamanetworkopen.2024.17625↗
  20. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampulla… Co-author DOI 10.1016/j.amjsurg.2024.115820↗
  21. Characteristics and prognosis of patients with pancreatic adenocarcinoma not expressing CA19-9: Analysis of the National Cancer Database. Last author DOI 10.1016/j.pan.2024.11.011↗
  22. Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1038/s41575-023-00856-2↗
  23. Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma: An Updated Nationwide Study. Last author DOI 10.1097/sla.0000000000005925↗
  24. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  25. Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy. Last author DOI 10.1245/s10434-024-15157-4↗
  26. ASO Author Reflections: Is There a Role for Selective Adjuvant Radiotherapy in the Modern Era of Pancreatic Cancer Treatment? Last author DOI 10.1245/s10434-024-15297-7↗
  27. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  28. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  29. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy. Last author DOI 10.1001/jamaoncol.2022.5808↗
  30. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ijrobp.2022.12.039↗
  31. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… First author DOI 10.1016/j.pan.2023.06.005↗
  32. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  33. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.05.008↗
  34. Advances in the management of pancreatic cancer. Co-author DOI 10.1136/bmj-2022-073995↗
  35. Comparison of Invasive Pancreatic Ductal Adenocarcinoma versus Intraductal Papillary Mucinous Neoplasm: A National Cancer Database Analysis. Last author DOI 10.3390/cancers15041185↗
  36. New criteria of resectability for pancreatic cancer: A position paper by the Japanese Society of Hepato-Biliary-Pancreatic Surgery (JSHBPS). First author DOI 10.1002/jhbp.1049↗
  37. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis. Last author DOI 10.1093/bjs/znac002↗
  38. Author response to: Comment on: Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Data… Last author DOI 10.1093/bjs/znac340↗
  39. Targeting Treg-Expressed STAT3 Enhances NK-Mediated Surveillance of Metastasis and Improves Therapeutic Response in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-2767↗
  40. Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleoti… Co-author DOI 10.1007/s00262-020-02701-w↗
  41. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreati… Co-author DOI 10.1016/j.hpb.2020.11.004↗
  42. Pancreatic cancer in patients with autoimmune pancreatitis: A scoping review. Co-author DOI 10.1016/j.pan.2021.03.007↗
  43. Outcome after resection for invasive intraductal papillary mucinous neoplasia is similar to conventional pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.07.009↗
  44. Metabolic Characterization of Plasma and Cyst Fluid from Cystic Precursors to Pancreatic Cancer Patients Reveal Metabolic Signatures of Bacterial Infection. Co-author DOI 10.1021/acs.jproteome.1c00018↗
  45. Isolation of pancreatic microbiota from cystic precursors of pancreatic cancer with intracellular growth and DNA damaging properties. Co-author DOI 10.1080/19490976.2021.1983101↗
  46. Outcome of neoadjuvant treatment for pancreatic cancer in elderly patients: comparative, observational cohort study. Last author DOI 10.1093/bjs/znab092↗
  47. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. Last author DOI 10.1097/sla.0000000000003301↗
  48. Induction of ADAM10 by Radiation Therapy Drives Fibrosis, Resistance, and Epithelial-to-Mesenchyal Transition in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-3892↗
  49. Landmark Series: Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-020-09535-x↗
  50. Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. Last author DOI 10.21037/jgo-21-119↗

Closest collaborators

The 25 strongest of 318 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Richard David Schulick · 34 shared papers, 2019–2026 · strength 6.63
  2. Oskar Franklin · 13 shared papers, 2024–2026 · strength 3.22
  3. Thomas F. Stoop · 13 shared papers, 2023–2026 · strength 2.68
  4. Toshitaka Sugawara · 11 shared papers, 2023–2026 · strength 2.29
  5. Hiroyuki Ishida · 8 shared papers, 2025–2026 · strength 2.24
  6. Marc G. Besselink · 16 shared papers, 2018–2026 · strength 2.20
  7. Atsushi Oba · 12 shared papers, 2020–2026 · strength 1.83
  8. Wells A. Messersmith · 10 shared papers, 2021–2026 · strength 1.70
  9. Christopher Lee Wolfgang · 10 shared papers, 2019–2026 · strength 1.63
  10. Sana D. Karam · 9 shared papers, 2021–2024 · strength 1.53
  11. Ana Gleisner · 8 shared papers, 2021–2026 · strength 1.47
  12. Bas Groot Koerkamp · 9 shared papers, 2019–2026 · strength 1.32
  13. Asif Halimi · 9 shared papers, 2019–2026 · strength 1.29
  14. Thilo Hackert · 9 shared papers, 2019–2026 · strength 1.24
  15. Poya Ghorbani · 7 shared papers, 2021–2026 · strength 1.21
  16. Izaak Quintus Molenaar · 7 shared papers, 2019–2026 · strength 1.17
  17. Ingmar Florin Rompen · 6 shared papers, 2025–2026 · strength 1.14
  18. Roeland F. de Wilde · 6 shared papers, 2024–2026 · strength 1.07
  19. Roberto Valente · 9 shared papers, 2017–2023 · strength 1.00
  20. Ammar A. Javed · 5 shared papers, 2025–2026 · strength 0.94
  21. Andrii Khomiak · 3 shared papers, 2025–2026 · strength 0.86
  22. Ernesto Sparrelid · 5 shared papers, 2021–2026 · strength 0.86
  23. Jin Peng He · 5 shared papers, 2020–2025 · strength 0.79
  24. Matthias J. Löhr · 8 shared papers, 2015–2021 · strength 0.73
  25. Casper H.J. van Eijck · 5 shared papers, 2019–2026 · strength 0.72

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.